No Data
No Data
Investors Might Be Losing Patience for Apellis Pharmaceuticals' (NASDAQ:APLS) Increasing Losses, as Stock Sheds 6.3% Over the Past Week
J.P. Morgan Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Announces Target Price $72
J.P. Morgan analyst Anupam Rama maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and sets the target price at $72.According to TipRanks data, the analyst has a success rate of 45.5% and
Express News | Apellis Pharmaceuticals Inc : JP Morgan Cuts Target Price to $72 From $79
Express News | Apellis Pharmaceuticals - Syfovre® (Pegcetacoplan Injection) Preserved Visual Function at 36 Months in Gale Extension Study in Geographic Atrophy (Ga)
SYFOVRE (Pegcetacoplan Injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpointData presented at the Clinical Trials at the Summit MeetingWALTHAM, Mass., June 10, 2024
Trending Stocks Today: Smartsheet Gets a 11.85% Boost Post-Market
June 5th - US stocks trending post-market.Gainers: $Smartsheet(SMAR.US)$ jumps 11.85% to $42.26 with a turnover of $13.32 million. $Lululemon Athletica(LULU.US)$ rises 10.5% to $340.65 with a turnover
No Data